Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924235 | 1.00 | TLR2 (0.46) | TLR2TLR1ALDH1A1HRH3SLC9A1 | |
| SCHEMBL4347292 | 0.86 | SIGMAR1 (0.46) | TLR2TLR1ALDH1A1HRH3SLC9A1 | |
| SCHEMBL29900799 | 0.85 | TLR2 (0.48) | TLR2TLR1ALDH1A1HRH3SIGMAR1 | |
| SCHEMBL3181923 | 0.84 | CYP1A2 (0.48) | TLR2TLR1ALDH1A1SLC9A1 | |
| SCHEMBL2148749 | 0.82 | TLR2 (0.41) | TLR2TLR1ALDH1A1HRH3SLC9A1 | |
| SCHEMBL15054630 | 0.82 | ALDH1A1 (0.40) | ALDH1A1PDE4BNPC1 | |
| SCHEMBL4342266 | 0.82 | ALDH1A1 (0.40) | ALDH1A1PDE4BNPC1 | |
| SCHEMBL9137609 | 0.81 | MEN1 (0.49) | ALDH1A1 | |
| SCHEMBL8783095 | 0.81 | MEN1 (0.49) | ALDH1A1 | |
| SCHEMBL15397583 | 0.81 | KDM1A (0.50) | TLR2TLR1ALDH1A1HRH3SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | TLR2 1856/4885TLR1 3477/4885ALDH1A1 2328/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | TLR2 1856/4885TLR1 3477/4885ALDH1A1 2328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.